StocksMedium•6 October 2026•
1 min read
Insmed Shares Decline Following Surprise Resignation of CFO
Key Facts
1Insmed shares declined following the announcement of the surprise exit of CFO Sara Bonstein.
2The company reaffirmed its 2026 revenue guidance for its drugs Brinsupri and Arikayce.
Insmed shares declined following the announcement of the surprise exit of CFO Sara Bonstein. Zacks reported that the company reaffirmed its 2026 revenue guidance for its drugs Brinsupri and Arikayce despite the leadership change.
INSM closed at $103.83 on October 5, 2026, with the session seeing a trading range between $101.65 and $108.75. The price action reflects market reaction to the unexpected executive transition in the finance department, which occurred alongside the maintenance of the company's long-term financial outlook.